Welcome to the first edition of this new unique journal which will cover clinical research, early innovations in clinical management key as well as timely and succinct educational updates. Gastrointestinal Oncology accounts for 25-35% of the cancer mortality worldwide. The field has developed particularly close multi-disciplinary team working on a clinical basis. Consequently, there have been pioneering developments in the diagnosis, prognostication and the therapeutic management of upper gastrointestinal, lower gastrointestinal, pancreato-hepatobiliary and other gastrointestinal associated oncological lesions.
The purpose of this journal is threefold;
To improve the best evidence available for clinical decision making
To highlight questions where urgent research is needed
To catalyse internal collaboration and networking including with patients and their careers.
The editorial board is made from experts from around the world so that the journal is applicable to the needs of the global community. Like me, they are drawn to this new venture because they recognise the unmet need, the global disparity in care coupled with the fast pace of new and effective diagnostic and therapies in gastrointestinal oncology. In the latter case, three particular examples seem prescient, novel imaging methods, immunotherapy and minimally invasive therapies.
We intend to explore innovative ways to make education and research relevant to everyone involved.
We aim to publish the highest quality articles in a very timely way and ensure that the article publicization is optimised. We are looking for several types of article. First, the best practice will be highlighted so as to rapidly set the standard for clinics globally. Second, is to fast-track new innovative studies that stimulate expansion of new subfields of research. Third, to improve educational updates by using the journal as a ‘repository of rapid and holistic updates’. Fourth, we hope that many articles will form a direct basis to help in the clinic with enhancing the doctor-patient-family relationship.
The ultimate aim is to maximise the impact in decreasing the global cancer burden.
We hope you sense the positive drive to enhance both the scope and depth of progress in gastrointestinal oncology. The journal will have an author friendly attitude and pre-submission enquiries are welcomed. We look forward to serving you in the coming years.
Funding source
N/A
Institute for Clinical Trials, University College London, London, United Kingdom
Dubai Medical College, Dubai, United Arab Emirates
[email protected]